Keros Therapeutics launches $5M share buyback after $20M milestone payment
Keros Therapeutics launched a $5 million share repurchase program after receiving a $20 million development milestone payment under a license agreement with Takeda Pharmaceuticals USA, following the dosing of the first patient.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.